Template:BerkiGEM2007 WikiPlaying

From 2007.igem.org

(Difference between revisions)
Line 129: Line 129:
position:absolute;
position:absolute;
left:299px;
left:299px;
-
top:110px;
+
top:99px;
width:305px;
width:305px;
height:348px;
height:348px;
Line 145: Line 145:
position:absolute;
position:absolute;
left:343px;
left:343px;
-
top:13px;
+
top:2px;
width:75px;
width:75px;
height:93px;
height:93px;
Line 186: Line 186:
position:absolute;
position:absolute;
left:210px;
left:210px;
-
top:128px;
+
top:117px;
width:84px;
width:84px;
height:91px;
height:91px;
Line 202: Line 202:
position:absolute;
position:absolute;
left:536px;
left:536px;
-
top:16px;
+
top:5px;
width:68px;
width:68px;
height:75px;
height:75px;
Line 210: Line 210:
position:absolute;
position:absolute;
left:589px;
left:589px;
-
top:190px;
+
top:179px;
width:88px;
width:88px;
height:125px;
height:125px;
Line 226: Line 226:
position:absolute;
position:absolute;
left:525px;
left:525px;
-
top:313px;
+
top:302px;
width:87px;
width:87px;
height:100px;
height:100px;
Line 250: Line 250:
#apDiv19 {
#apDiv19 {
position:absolute;
position:absolute;
-
left:289px;
+
left:290px;
-
top:381px;
+
top:370px;
width:86px;
width:86px;
height:105px;
height:105px;
Line 258: Line 258:
#apDiv20 {
#apDiv20 {
position:absolute;
position:absolute;
-
left:443px;
+
left:444px;
-
top:380px;
+
top:368px;
width:114px;
width:114px;
height:101px;
height:101px;
Line 390: Line 390:
#apDiv36 {
#apDiv36 {
position:absolute;
position:absolute;
-
left:558px;
+
left:552px;
-
top:514px;
+
top:406px;
width:183px;
width:183px;
height:52px;
height:52px;
Line 423: Line 423:
#apDiv40 {
#apDiv40 {
position:absolute;
position:absolute;
-
left:276px;
+
left:152px;
-
top:571px;
+
top:473px;
width:328px;
width:328px;
height:17px;
height:17px;
Line 434: Line 434:
top:1px;
top:1px;
width:209px;
width:209px;
-
height:585px;
+
height:490px;
z-index:35;
z-index:35;
background-color: #FFFF00;
background-color: #FFFF00;
Line 500: Line 500:
#apDiv48 {
#apDiv48 {
position:absolute;
position:absolute;
-
left:155px;
+
left:0px;
-
top:20px;
+
top:0px;
-
width:96px;
+
width:149px;
-
height:72px;
+
height:97px;
-
z-index:42;
+
z-index:99;
}
}
#apDiv49 {
#apDiv49 {
Line 519: Line 519:
top:1px;
top:1px;
width:149px;
width:149px;
-
height:587px;
+
height:489px;
z-index:43;
z-index:43;
background-color: #0000FF;
background-color: #0000FF;
}
}
.style12 {
.style12 {
-
font-size: small;
+
font-size: x-small;
font-weight: bold;
font-weight: bold;
color: #FFFF00;
color: #FFFF00;
}
}
-
.style13 {font-size: small}
 
.style15 {font-size: medium; color: #0000FF; }
.style15 {font-size: medium; color: #0000FF; }
.style16 {font-size: x-small}
.style16 {font-size: x-small}
Line 574: Line 573:
   <div align="justify"><span class="style15"><strong>The global demand and importance</strong> for cheap, available, and  disease free blood substitutes is undisputed. There are currently no  red blood cell substitutes approved for clinical use in the US or the  UK, and whole blood is almost always in short supply. Underdeveloped  countries that need blood the most simply don’t have the infrastructure  to support donation and storage, in addition a sizeable fraction of the  population are disease carriers. We are developing an innovative and  cheap blood substitute based on engineered <em>E. coli</em> with all the  critical properties of human erythrocytes. These include the ability to  safely exist in the bloodstream, carry oxygen, and be stored for  prolonged periods in a freeze-dried state.</span></div>
   <div align="justify"><span class="style15"><strong>The global demand and importance</strong> for cheap, available, and  disease free blood substitutes is undisputed. There are currently no  red blood cell substitutes approved for clinical use in the US or the  UK, and whole blood is almost always in short supply. Underdeveloped  countries that need blood the most simply don’t have the infrastructure  to support donation and storage, in addition a sizeable fraction of the  population are disease carriers. We are developing an innovative and  cheap blood substitute based on engineered <em>E. coli</em> with all the  critical properties of human erythrocytes. These include the ability to  safely exist in the bloodstream, carry oxygen, and be stored for  prolonged periods in a freeze-dried state.</span></div>
</div>
</div>
-
<div id="apDiv48"><img name="BloodyiGEMLogo" src="https://static.igem.org/mediawiki/2007/1/10/MovingiGEMlogo.gif" width="95" height="70" alt=""></div>
 
<div class="style12" id="apDiv50">
<div class="style12" id="apDiv50">
-
   <p>Introduction</p>
+
   <p><a href="https://2007.igem.org/Berkeley_UC_Introduction">Introduction</a></p>
-
   <p>Oxygen Transport  </p>
+
   <p><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport">Oxygen Transport  </a></p>
   <ul>
   <ul>
-
     <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Hemoglobin" class="style13">Hemoglobin</a></li>
+
     <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Hemoglobin">Hemoglobin</a></li>
     <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Chaperones">Chaperones
     <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Chaperones">Chaperones
       </a>
       </a>
       <ul>
       <ul>
-
         <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Chaperones_Heme" class="style13">Heme</a></li>
+
         <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Chaperones_Heme">Heme</a></li>
-
         <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Chaperones_AHSP" class="style13">AHSP<br>
+
         <li><a href="https://2007.igem.org/Berkeley_UC_OxygenTransport_Chaperones_AHSP">AHSP<br>
           </a> </li>
           </a> </li>
       </ul>
       </ul>
     </li>
     </li>
   </ul>
   </ul>
-
   <p class="style13">Immunity</p>
+
   <p><a href="https://2007.igem.org/Berkeley_UC_Immunity">Immunity</a></p>
 +
  <ul>
 +
    <li><a href="https://2007.igem.org/Berkeley_UC_Immunity_Chassis">Chassis</a></li>
 +
    <li><a href="https://2007.igem.org/Berkeley_UC_Immunity_msbBDeletion">msbB Deletion</a></li>
 +
  </ul>
 +
  <p><a href="https://2007.igem.org/Berkeley_UC_Antioxidants">Antioxidants</a></p>
 +
  <ul>
 +
    <li><a href="https://2007.igem.org/Berkeley_UC_Antioxidants_SodC">SodC</a></li>
 +
    <li><a href="https://2007.igem.org/Berkeley_UC_Antioxidants_KatG">KatG</a></li>
 +
  </ul>
 +
  <p><a href="https://2007.igem.org/Berkeley_UC_GrowthControl">Growth Control</a></p>
   <ul>
   <ul>
-
     <li>Chassis</li>
+
     <li><a href="https://2007.igem.org/Berkeley_UC_GrowthControl_tonBDeletion">tonB Deletion</a></li>
-
     <li>msbB Deletion</li>
+
     <li><a href="https://2007.igem.org/Berkeley_UC_GrowthControl_dapDDeletion">dapD Deletion</a></li>
 +
    <li><a href="https://2007.igem.org/Berkeley_UC_KillSwitch">&quot;Kill&quot; Switch</a></li>
   </ul>
   </ul>
-
   <p class="style13">Antioxidants</p>
+
   <p><a href="https://2007.igem.org/Berkeley_UC_SystemController">SystemController</a></p>
   <ul>
   <ul>
-
     <li>SodC/KatG</li>
+
     <li><a href="https://2007.igem.org/Berkeley_UC_SystemController_PirT7System">pir/T7 System</a></li>
   </ul>
   </ul>
-
   <p class="style13">Growth Control</p>
+
   <p><a href="https://2007.igem.org/Berkeley_UC_Storage">Storage</a></p>
   <ul>
   <ul>
-
     <li>tonB Deletion</li>
+
     <li><a href="https://2007.igem.org/Berkeley_UC_Storage_FreezeDrying">Freeze Drying</a></li>
-
    <li>dapD Deletion</li>
+
   </ul>
   </ul>
-
  <p class="style13"><a href="https://2007.igem.org/Berkeley_UC_KillSwitch">Kill Switch</a></p>
 
-
  <p class="style13"><a href="https://2007.igem.org/Berkeley_UC_SystemController">SystemController</a></p>
 
-
  <p class="style13"><a href="https://2007.igem.org/Berkeley_UC_Storage">Storage</a></p>
 
</div>
</div>
</body>
</body>

Revision as of 00:26, 9 October 2007












Untitled Document

Best viewed in the most recent version of firefox, because IE sucks.
The global demand and importance for cheap, available, and disease free blood substitutes is undisputed. There are currently no red blood cell substitutes approved for clinical use in the US or the UK, and whole blood is almost always in short supply. Underdeveloped countries that need blood the most simply don’t have the infrastructure to support donation and storage, in addition a sizeable fraction of the population are disease carriers. We are developing an innovative and cheap blood substitute based on engineered E. coli with all the critical properties of human erythrocytes. These include the ability to safely exist in the bloodstream, carry oxygen, and be stored for prolonged periods in a freeze-dried state.



























































Retrieved from "http://2007.igem.org/wiki/index.php/Template:BerkiGEM2007_WikiPlaying"